Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Eli Lilly (LLY) , which belongs to the Zacks Large Cap Pharmaceuticals industry.This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 14.54%.For the last reported quarter, Lilly came out with earnings of $7.02 per share versus the Zacks Conse ...

Core Viewpoint - AbbVie (ABBV) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings expected to be $3.02 per share, reflecting a +39.8% change, and revenues projected at $16.38 billion, up 8.5% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 4, and the stock may rise if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 0.32% higher in the last 30 days, indicating a slight positive adjustment from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that AbbVie has a negative Earnings ESP of -12.44%, suggesting analysts have become bearish on the company's earnings prospects [12]. - Despite the negative Earnings ESP, AbbVie holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - AbbVie has a history of beating consensus EPS estimates, having done so in the last four quarters, with a recent surprise of +5.08% when it reported earnings of $1.86 per share against an expectation of $1.77 [13][14]. Industry Context - In the broader pharmaceutical industry, Merck (MRK) is also expected to report earnings of $2.04 per share for the same quarter, reflecting a year-over-year change of +18.6%, with revenues projected at $16.19 billion, up 3.6% [18]. - Merck's consensus EPS estimate has been revised down by 85.2% over the last 30 days, and it currently has an Earnings ESP of +0.33% but holds a Zacks Rank of 4, complicating predictions for an earnings beat [19][20].

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.05%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.77 per share when it actually produced earnings of $2.8, delivering a surprise of +1.08%.Ove ...

Company Overview - Arcellx, Inc. (ACLX) is part of the Medical group, which consists of 932 companies and currently ranks 8 within the Zacks Sector Rank [2] - The company belongs to the Medical - Biomedical and Genetics industry, which includes 453 companies and is ranked 93 in the Zacks Industry Rank [6] Performance Metrics - Year-to-date, Arcellx, Inc. has returned approximately 10.7%, outperforming the average gain of 6% for Medical stocks [4] - The Zacks Consensus Estimate for ACLX's full-year earnings has increased by 1.2% over the past quarter, indicating improved analyst sentiment [4] Comparison with Peers - Bayer Aktiengesellschaft (BAYRY), another Medical stock, has outperformed the sector with a year-to-date return of 15.6% and a Zacks Rank of 1 (Strong Buy) [5] - The Large Cap Pharmaceuticals industry, which includes Bayer, has gained 19.8% since the beginning of the year, while Arcellx, Inc. is slightly underperforming its industry group [6][7]

Wall Street expects a year-over-year increase in earnings on higher revenues when Johnson & Johnson (JNJ) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Janua ...

Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.16%. On the other hand, the Dow registered a gain of 0.17%, and the technology-centric Nasdaq increased by 0.26%. Prior to today's trading, shares of the world's biggest maker of health care products had lost 3.4% lagged the Medical sector's gain of 2.84% and the S&P 500's gain of 1.89%.The upcoming earnings release of Johnson & Johnson will ...

Core Viewpoint - Merck is experiencing positive stock performance, with a notable increase in share price and projected earnings growth, indicating strong investor interest and optimism in the company's future performance [1][2][3]. Group 1: Stock Performance - Merck's stock closed at $110.99, reflecting a 2.2% increase from the previous trading session, outperforming the S&P 500's gain of 0.01% [1]. - Over the prior period, Merck's shares have risen by 11.25%, significantly exceeding the Medical sector's gain of 2.01% and the S&P 500's gain of 0.86% [1]. Group 2: Earnings Projections - Merck is expected to report earnings of $2.08 per share on February 3, 2026, representing a year-over-year growth of 20.93% [2]. - The consensus estimate for revenue is projected at $16.18 billion, indicating a 3.56% increase from the same quarter last year [2]. Group 3: Annual Forecasts - For the entire year, Zacks Consensus Estimates forecast earnings of $8.98 per share and revenue of $64.81 billion, reflecting changes of +17.39% and 0%, respectively, compared to the previous year [3]. - Recent adjustments to analyst estimates for Merck indicate a dynamic business environment, with positive revisions suggesting analyst optimism regarding profitability [3]. Group 4: Valuation Metrics - Merck's Forward P/E ratio stands at 12.97, which is below the industry average Forward P/E of 15.6, indicating a potential valuation discount [6]. - The PEG ratio for Merck is currently 1.11, compared to the Large Cap Pharmaceuticals industry average of 1.59, suggesting a favorable growth outlook relative to its price [6]. Group 5: Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 168, placing it in the bottom 32% of over 250 industries [7]. - The Zacks Industry Rank assesses the performance of industry groups, with top-rated industries historically outperforming lower-rated ones by a factor of 2 to 1 [7].

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Company Performance - Merck (MRK) closed at $106.45, reflecting a +1.34% change from the previous day, outperforming the S&P 500's gain of 0.32% [1] - The stock has decreased by 0.59% over the past month, underperforming the Medical sector's increase of 1.67% and the S&P 500's rise of 4.7% [1] Upcoming Earnings - Merck's upcoming EPS is projected at $2.08, indicating a 20.93% increase compared to the same quarter last year [2] - Revenue is expected to reach $16.18 billion, representing a 3.56% increase from the year-ago quarter [2] Full Year Projections - For the full year, earnings are projected at $8.98 per share and revenue at $64.81 billion, reflecting increases of +17.39% and +1% respectively from the prior year [3] - Recent analyst estimate revisions suggest positive sentiment towards Merck's business operations and profit generation capabilities [3] Valuation Metrics - Merck's Forward P/E ratio stands at 11.7, which is below the industry average of 14.45, indicating a discount relative to its peers [6] - The company has a PEG ratio of 1, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.64 [7] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 161, placing it in the bottom 35% of over 250 industries [8] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, with higher-ranked industries outperforming lower-ranked ones [8]